EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers

Pavlina Spiliopoulou iD, Olga Vornicova, Sofia Genta, Anna Spreafico iD

International Journal of Molecular Sciences · 09.01.2023 · 24 (2) · 1294

DOI: 10.3390/ijms24021294 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.01.2023. Verfasst von Pavlina Spiliopoulou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 270 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advances in treating cutaneous melanoma have resulted in impressive patient survival gains. Refinement of disease staging and accurate patient risk classification have significantly improved our prognostic knowledge and ability to accurately stratify treatment. Undoubtedly, the most important step towards optimizing patient outcomes has been the advent of cancer immunotherapy, in the form of immune checkpoint inhibition (ICI). Immunotherapy has established its cardinal role in the management of both early and late-stage melanoma. Through leveraging outcomes in melanoma, immunotherapy has also extended its benefit to other types of skin cancers. In this review, we endeavor to summarize the current role of immunotherapy in melanoma and non-melanoma skin cancers, highlight the most pertinent immunotherapy-related molecular biomarkers, and lastly, shed light on future research directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansBiomarkers, TumorImmunotherapy

Stichwörter der Autor:innen

biomarkers of immunotherapy resistancebiomarkers of immunotherapy responsecirculating tumor DNAmelanoma and non-melanoma skin cancersmicrobiomenovel immune checkpoints

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Mount Sinai Hospital, University Health Network, Toronto, ON M5G 1X5, Canada.

ORCID-Profile: Pavlina Spiliopoulou, Anna Spreafico

Zitieren

APA

Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023). Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. International Journal of Molecular Sciences, 24(2), 1294. https://doi.org/10.3390/ijms24021294

Vancouver

Spiliopoulou P, Vornicova O, Genta S, Spreafico A. Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. International Journal of Molecular Sciences. 2023;24(2):1294. doi:10.3390/ijms24021294

BibTeX
@article{Spiliopoulou2023,
  author = {Spiliopoulou, Pavlina and Vornicova, Olga and Genta, Sofia and Spreafico, Anna},
  title = {Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {2},
  pages = {1294},
  doi = {10.3390/ijms24021294}
}
Kostenlos starten →